148 related articles for article (PubMed ID: 16333039)
1. Re: Cetuximab therapy and symptomatic hypomagnesemia.
Altundag K; Altundag O; Baptista MZ; Turen S; Atik MA
J Natl Cancer Inst; 2005 Dec; 97(23):1791-2. PubMed ID: 16333039
[No Abstract] [Full Text] [Related]
2. Cetuximab therapy and symptomatic hypomagnesemia.
Schrag D; Chung KY; Flombaum C; Saltz L
J Natl Cancer Inst; 2005 Aug; 97(16):1221-4. PubMed ID: 16106027
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR monoclonal antibody-induced hypomagnesaemia.
Fakih M
Lancet Oncol; 2007 May; 8(5):366-7. PubMed ID: 17466890
[No Abstract] [Full Text] [Related]
4. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
5. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S9-19. PubMed ID: 21843103
[TBL] [Abstract][Full Text] [Related]
6. Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.
Fakih M
Oncology (Williston Park); 2008 Jan; 22(1):74-6. PubMed ID: 18251285
[No Abstract] [Full Text] [Related]
7. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Dunsford J
Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
[No Abstract] [Full Text] [Related]
8. Nondermatologic adverse events associated with anti-EGFR therapy.
Sandler AB
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):35-40. PubMed ID: 16736981
[TBL] [Abstract][Full Text] [Related]
9. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Tamura T
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Cohen RB
Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
12. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
16. Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.
do Pazo-Oubiña F; Estefanell-Tejero A; Riu-Viladoms G; Anglada-Martínez H; Molas-Ferrer G; Creus-Baró N
J Clin Pharm Ther; 2013 Apr; 38(2):101-3. PubMed ID: 23278401
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
18. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Morse L
ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155
[No Abstract] [Full Text] [Related]
19. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
Tejpar S; Piessevaux H; Claes K; Piront P; Hoenderop JG; Verslype C; Van Cutsem E
Lancet Oncol; 2007 May; 8(5):387-94. PubMed ID: 17466895
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib versus cetuximab in lung cancer: round one.
Minna JD; Peyton MJ; Gazdar AF
J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
[No Abstract] [Full Text] [Related]
[Next] [New Search]
